Your session is about to expire
← Back to Search
BL-8040 for Pancreatic Cancer (COMBAT Trial)
COMBAT Trial Summary
This trial will study two different combinations of drugs to treat metastatic pancreatic cancer. The first combination is of BL-8040 with pembrolizumab, and the second is of BL-8040 with liposomal irinotecan, 5-fluorouracil, and leucovorin. The trial will assess the safety and efficacy of these combinations.
COMBAT Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowCOMBAT Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.COMBAT Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Could you elaborate on the typical applications of Pembrolizumab?
"Pembrolizumab is an effective pharmacological solution for malignant neoplasms, unresectable melanoma, and those with microsatellite instability high."
Has Pembrolizumab met the criteria to receive authorization from the FDA?
"The team at Power has assigned pembrolizumab a rating of 2, given that this is a Phase 2 clinical trial and there have been some findings indicating safety but no evidence backing efficacy."
Could you delineate the past experiments involving Pembrolizumab?
"Presently, 1346 clinical trials are available to test the efficacy of Pembrolizumab. Among those studies, 225 are currently in their final testing phase (Phase 3). This treatment is being tested at 52547 medical sites across the United States with a concentration near Houston, Texas."
How many facilities are engaged in the management of this clinical trial?
"This clinical study is currently enrolling patients across 15 different sites. Some of the primary locations are Massachusetts General Hospital (MGH) in Boston, Beth Israel Deaconess Medical Center (BIDMAC) in Scottsdale and Honor Health in Phoenix."
Is there still an opportunity to join this medical experiment?
"Unfortunately, this trial is not accepting participants at this time. It was initially posted on September 1st 2016 and most recently amended on April 27th 2022. If you are seeking other studies, 45 clinical trials for neoplasm metastasis and 1346 Pembrolizumab studies are currently recruiting patients."
What is the enrollment quota for this medical investigation?
"This trial is no longer open for enrolment. It was first posted on September 1st 2016 and last edited April 27th 2022. If you're looking to join other studies, there are 45 trials actively searching for patients with neoplasm metastasis and 1346 related to Pembrolizumab that require volunteers."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger